Outcomes of Proton Beam Radiotherapy for Large Non-Peripapillary Choroidal and Ciliary Body Melanoma at TRIUMF and the BC Cancer Agency

Overview

Journal Ocul Oncol Pathol

Date 2016 May 13

PMID 27171272

Citations 9

Authors

Britta Weber

Katherine Paton

Roy Ma

Tom Pickles

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: To report outcomes and toxicity after proton beam radiotherapy for non-peripapillary choroidal and ciliary body melanoma considered unsuitable for other eye-sparing therapies.

Materials And Methods: An existing database of 77 patients with non-peripapillary tumors treated at TRIUMF, Canada, including patient, tumor, and treatment characteristics, was updated with ocular complications and follow-up status from chart reviews.

Results: Most of the patients had large tumors: 61% were T3/T4 tumors (AJCC classification), while 48% were large by the Collaborative Ocular Melanoma Study classification. The median thickness was 7.1 mm, and the ciliary body was involved in 35%. After 5 and 10 years, the actuarial ocular tumor control rate was 85 and 85%, metastasis-free survival was 72 and 57%, overall survival was 77 and 63%, the enucleation rate was 22 and 22%, and complete blindness was found in 38 and 38%, respectively. On univariate analysis, patients with ciliary body involvement had significantly worse metastasis-free survival and overall survival rates compared to patients without ciliary body involvement (p < 0.001).

Conclusions: Proton therapy for large anteriorly located tumors resulted in acceptable ocular tumor control and survival rates. The risk of blindness and severe toxicity requiring enucleation was low, and a substantial proportion of patients maintained useful vision.

Citing Articles

Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives.

Kulbay M, Marcotte E, Remtulla R, Lau T, Paez-Escamilla M, Wu K Biomedicines. 2024; 12(8).

PMID: 39200222 PMC: 11352094. DOI: 10.3390/biomedicines12081758.

Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma.

Tseng Y, Hsu C, Chou Y Eye (Lond). 2024; 38(10):1882-1890.

PMID: 38565600 PMC: 11226678. DOI: 10.1038/s41433-024-03035-y.

Radiation treatment methods in uveal melanoma.

Tsotridou E, Loukovitis E, Tsiropoulos G, Zapsalis K, Pentara I, Tzima K Med Hypothesis Discov Innov Ophthalmol. 2023; 10(1):32-42.

PMID: 37641625 PMC: 10460216. DOI: 10.51329/mehdiophthal1419.

Radiotherapy in Uveal Melanoma: A Review of Ocular Complications.

Banou L, Tsani Z, Arvanitogiannis K, Pavlaki M, Dastiridou A, Androudi S Curr Oncol. 2023; 30(7):6374-6396.

PMID: 37504330 PMC: 10378371. DOI: 10.3390/curroncol30070470.

Ocular Complications of Radiotherapy in Uveal Melanoma.

Zemba M, Dumitrescu O, Gheorghe A, Radu M, Ionescu M, Vatafu A Cancers (Basel). 2023; 15(2).

PMID: 36672282 PMC: 9856287. DOI: 10.3390/cancers15020333.

References

Jampol L, Moy C, Murray T, Reynolds S, Albert D, Schachat A . The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002; 109(12):2197-206. DOI: 10.1016/s0161-6420(02)01277-0. View

Tran E, Ma R, Paton K, Blackmore E, Pickles T . Outcomes of proton radiation therapy for peripapillary choroidal melanoma at the BC Cancer Agency. Int J Radiat Oncol Biol Phys. 2012; 83(5):1425-31. DOI: 10.1016/j.ijrobp.2011.10.017. View

Shammas H, Blodi F . Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol. 1977; 95(1):63-9. DOI: 10.1001/archopht.1977.04450010065005. View

Field M, Harbour J . Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014; 25(3):234-9. PMC: 4467564. DOI: 10.1097/ICU.0000000000000051. View

Egger E, Schalenbourg A, Zografos L, BERCHER L, Boehringer T, Chamot L . Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys. 2001; 51(1):138-47. DOI: 10.1016/s0360-3016(01)01560-7. View

Goitein M, Miller T . Planning proton therapy of the eye. Med Phys. 1983; 10(3):275-83. DOI: 10.1118/1.595258. View

Damato B, Kacperek A, Errington D, Heimann H . Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol. 2013; 27(3):151-7. PMC: 3770228. DOI: 10.1016/j.sjopt.2013.06.014. View

Macdonald E, Cauchi P, Kemp E . Proton beam therapy for the treatment of uveal melanoma in Scotland. Br J Ophthalmol. 2011; 95(12):1691-5. DOI: 10.1136/bjo.2010.195594. View

Muller K, Nowak P, de Pan C, Marijnissen J, Paridaens D, Levendag P . Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2005; 63(1):116-22. DOI: 10.1016/j.ijrobp.2005.01.058. View

10.

Gragoudas E, Li W, Goitein M, Lane A, Munzenrider J, Egan K . Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002; 120(12):1665-71. DOI: 10.1001/archopht.120.12.1665. View

11.

Wouters B, Lam G, Oelfke U, Gardey K, Durand R, SKARSGARD L . Measurements of relative biological effectiveness of the 70 MeV proton beam at TRIUMF using Chinese hamster V79 cells and the high-precision cell sorter assay. Radiat Res. 1996; 146(2):159-70. View

12.

Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E . Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114(12):2309-15. DOI: 10.1016/j.ophtha.2007.01.032. View

13.

Caujolle J, Mammar H, Chamorey E, Pinon F, Herault J, Gastaud P . Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience. Int J Radiat Oncol Biol Phys. 2009; 78(1):98-103. DOI: 10.1016/j.ijrobp.2009.07.1688. View

14.

Char D, Quivey J, Castro J, Kroll S, Phillips T . Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology. 1993; 100(10):1547-54. DOI: 10.1016/s0161-6420(93)31446-6. View

15.

Damato B, Heimann H, Kalirai H, Coupland S . Age, survival predictors, and metastatic death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival. JAMA Ophthalmol. 2014; 132(5):605-13. DOI: 10.1001/jamaophthalmol.2014.77. View

16.

Muller K, Naus N, Nowak P, Schmitz P, de Pan C, van Santen C . Fractionated stereotactic radiotherapy for uveal melanoma, late clinical results. Radiother Oncol. 2011; 102(2):219-24. DOI: 10.1016/j.radonc.2011.06.038. View

17.

Li W, Gragoudas E, Egan K . Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol. 2000; 118(8):1066-70. DOI: 10.1001/archopht.118.8.1066. View

18.

Dendale R, Lumbroso-Le Rouic L, Noel G, Feuvret L, Levy C, Delacroix S . Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys. 2006; 65(3):780-7. DOI: 10.1016/j.ijrobp.2006.01.020. View

19.

Seddon J, Albert D, Lavin P, Robinson N . A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol. 1983; 101(12):1894-9. DOI: 10.1001/archopht.1983.01040020896012. View

20.

Mellen P, Morton S, Shields C . American joint committee on cancer staging of uveal melanoma. Oman J Ophthalmol. 2013; 6(2):116-8. PMC: 3779409. DOI: 10.4103/0974-620X.116652. View